Evidence Weighed for Suicide/Self-Harm With Obesity Drugs

As the EU looks into cases of suicidal thoughts and self-harm associated with the GLP-1 agonists semaglutide, and liraglutide, Novo Nordisk says it is confident of the risk-benefit profile of these agents.
Medscape Medical News

source https://www.medscape.com/viewarticle/994266?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost